Literature DB >> 22627470

Changes in von Willebrand factor-cleaving protease (ADAMTS-13) in patients with aortic stenosis undergoing valve replacement or balloon valvuloplasty.

Jeffrey Bander1, Sammy Elmariah, Louis M Aledort, Jeffrey Dlott, Paul Stelzer, Jonathan L Halperin, Annapoorna S Kini, Samin K Sharma.   

Abstract

It was the objective of this study to determine whether reduced cleavage of von Willebrand factor (VWF) multimers following aortic valve replacement (AVR) is a consequence of reduced shear stress or postoperative changes in VWF cleavage protease (ADAMTS-13) activity. Aortic stenosis (AS) may be complicated by acquired von Willebrand disease. Aortic valve replacement (AVR) corrects the associated haematologic abnormalities. We enrolled 114 patients with severe AS scheduled for either balloon aortic valvuloplasty (BAV; n=64) or AVR (n=50). Haematologic assessments of VWF levels and activity and ADAMTS-13 were performed before and 24 hours after valve intervention. The VWF:RCo to VWF:Ag ratio, a surrogate for large VWF multimer activity, increased by 37% (p < 0.0001) after AVR and by 10% (p = 0.0002) after BAV. ADAMTS-13 activity significantly decreased after AVR (579 ± 127 to 468 ± 135 ng/ml; p<0.0001), but not after BAV (484 ± 153 to 529 ± 185 ng/ml; p = 0.10). By multivariable analysis, the change in VWF:RCo ratio after AVR was more strongly associated with the fall in ADAMTS-13 than with reduction of valve gradient; whereas the change in gradient better predicted the rise in VWF:RCo after BAV. In conclusion, both BAV and AVR reverse the haematological abnormalities of the acquired von Willebrand syndrome of AS and ADAMTS-13 levels decrease after AVR. These findings suggest that a portion of the haematologic benefit of AVR may be due to a postoperative decline in ADAMTS-13 rather than solely to relief of AS as previously thought.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22627470     DOI: 10.1160/TH11-12-0803

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  Characterization of Von Willebrand Factor Multimer Structure in Patients With Severe Aortic Stenosis.

Authors:  Joerg Kellermair; Helmut W Ott; Michael Spannagl; Josef Tomasits; Juergen Kammler; Hermann Blessberger; Christian Reiter; Clemens Steinwender
Journal:  Clin Appl Thromb Hemost       Date:  2017-12-04       Impact factor: 2.389

2.  Pre-procedural abnormal function of von Willebrand Factor is predictive of bleeding after surgical but not transcatheter aortic valve replacement.

Authors:  Kajetan Grodecki; Karol Zbroński; Elżbieta Przybyszewska-Kazulak; Anna Olasińska-Wiśniewska; Radosław Wilimski; Bartosz Rymuza; Piotr Scisło; Paweł Czub; Dominika Koper; Janusz Kochman; Katarzyna Pawlak; Olga Ciepiela; Marek Grygier; Marek Jemielity; Maciej Lesiak; Krzysztof J Filipiak; Grzegorz Opolski; Zenon Huczek
Journal:  J Thromb Thrombolysis       Date:  2019-11       Impact factor: 2.300

Review 3.  Acquired Von Willebrand Deficiency in Adults With Aortic Stenosis: A Systematic Review.

Authors:  Prasana Ramesh; Suthasenthuran Kanagalingam; Fnu Zargham Ul Haq; Nishok Victory Srinivasan; Aujala Irfan Khan; Ghadi D Mashat; Mohammad Hazique; Kokab Irfan Khan; Safeera Khan
Journal:  Cureus       Date:  2022-09-07

4.  Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.

Authors:  Joshua A Beckman; Brian R Wood; Kevin L Ard; Christin N Price; Daniel A Solomon; Jonah P Zuflacht; Jessica Milian; Joshua C Prenner; Paul E Sax
Journal:  PLoS One       Date:  2017-10-12       Impact factor: 3.240

5.  Multiple biomarker panel to screen for severe aortic stenosis: results from the CASABLANCA study.

Authors:  Sammy Elmariah; Cian McCarthy; Nasrien Ibrahim; Deborah Furman; Renata Mukai; Craig Magaret; Rhonda Rhyne; Grady Barnes; Roland R J van Kimmenade; James L Januzzi
Journal:  Open Heart       Date:  2018-11-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.